{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:56:36Z","timestamp":1780505796086,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11060-019-03300-1","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T23:21:15Z","timestamp":1569885675000},"page":"339-347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Underweight and weight loss are predictors of poor outcome in patients with brain metastasis"],"prefix":"10.1007","volume":"145","author":[{"given":"Anna","family":"Lareida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Terziev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Grossenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Andratschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Rohrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Stahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9024-8736","authenticated-orcid":false,"given":"Fabian","family":"Wolpert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"3300_CR1","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/neuonc\/nos087","volume":"14","author":"JS Barnholtz-Sloan","year":"2012","unstructured":"Barnholtz-Sloan JS, Yu C, Sloan AE, Vengoechea J, Wang M, Dignam JJ, Vogelbaum MA, Sperduto PW, Mehta MP, Machtay M, Kattan MW (2012) A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro-oncology 14:910\u2013918. \nhttps:\/\/doi.org\/10.1093\/neuonc\/nos087","journal-title":"Neuro-oncology"},{"key":"3300_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11060-004-8093-6","volume":"75","author":"IT Gavrilovic","year":"2005","unstructured":"Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5\u201314. \nhttps:\/\/doi.org\/10.1007\/s11060-004-8093-6","journal-title":"J Neurooncol"},{"key":"3300_CR3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ijrobp.2007.06.074","volume":"70","author":"PW Sperduto","year":"2008","unstructured":"Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510\u2013514. \nhttps:\/\/doi.org\/10.1016\/j.ijrobp.2007.06.074","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3300_CR4","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1158\/1055-9965.EPI-17-0200","volume":"26","author":"BJ Caan","year":"2017","unstructured":"Caan BJ, Meyerhardt JA, Kroenke CH, Alexeeff S, Xiao J, Weltzien E, Feliciano EC, Castillo AL, Quesenberry CP, Kwan ML, Prado CM (2017) Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study). Cancer Epidemiol Biomarkers Prev 26:1008\u20131015. \nhttps:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0200","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3300_CR5","doi-asserted-by":"publisher","first-page":"e1769","DOI":"10.1097\/MD.0000000000001769","volume":"94","author":"HN Chen","year":"2015","unstructured":"Chen HN, Chen XZ, Zhang WH, Yang K, Chen XL, Zhang B, Chen ZX, Chen JP, Zhou ZG, Hu JK (2015) The impact of body mass index on the surgical outcomes of patients with gastric cancer: a 10-year single-institution cohort study. Medicine (Baltimore) 94:e1769. \nhttps:\/\/doi.org\/10.1097\/MD.0000000000001769","journal-title":"Medicine (Baltimore)"},{"key":"3300_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/JTO.0b013e31829cf942","volume":"8","author":"SE Dahlberg","year":"2013","unstructured":"Dahlberg SE, Schiller JH, Bonomi PB, Sandler AB, Brahmer JR, Ramalingam SS, Johnson DH (2013) Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials. J Thorac Oncol 8:1121\u20131127. \nhttps:\/\/doi.org\/10.1097\/JTO.0b013e31829cf942","journal-title":"J Thorac Oncol"},{"key":"3300_CR7","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00432-014-1878-x","volume":"141","author":"L Miao","year":"2015","unstructured":"Miao L, Chen H, Xiang J, Zhang Y (2015) A high body mass index in esophageal cancer patients is not associated with adverse outcomes following esophagectomy. J Cancer Res Clin Oncol 141:941\u2013950. \nhttps:\/\/doi.org\/10.1007\/s00432-014-1878-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"3300_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/cam4.634","volume":"5","author":"NM Tsang","year":"2016","unstructured":"Tsang NM, Pai PC, Chuang CC, Chuang WC, Tseng CK, Chang KP, Yen TC, Lin JD, Chang JT (2016) Overweight and obesity predict better overall survival rates in cancer patients with distant metastases. Cancer Med 5:665\u2013675. \nhttps:\/\/doi.org\/10.1002\/cam4.634","journal-title":"Cancer Med"},{"key":"3300_CR9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ijo.2015.205","volume":"40","author":"MJ Chen","year":"2016","unstructured":"Chen MJ, Wu WY, Yen AM, Fann JC, Chen SL, Chiu SY, Chen HH, Chiou ST (2016) Body mass index and breast cancer: analysis of a nation-wide population-based prospective cohort study on 1 393 985 Taiwanese women. Int J Obes (Lond) 40:524\u2013530. \nhttps:\/\/doi.org\/10.1038\/ijo.2015.205","journal-title":"Int J Obes (Lond)"},{"key":"3300_CR10","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1210\/en.2009-0070","volume":"150","author":"MP Cleary","year":"2009","unstructured":"Cleary MP, Grossmann ME (2009) Minireview: Obesity and breast cancer: the estrogen connection. Endocrinology 150:2537\u20132542. \nhttps:\/\/doi.org\/10.1210\/en.2009-0070","journal-title":"Endocrinology"},{"key":"3300_CR11","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s10552-010-9639-x","volume":"21","author":"LW Jones","year":"2010","unstructured":"Jones LW, Ali-Osman F, Lipp E, Marcello JE, McCarthy B, McCoy L, Rice T, Wrensch M, Il'yasova D (2010) Association between body mass index and mortality in patients with glioblastoma mutliforme. Cancer Causes Control 21:2195\u20132201. \nhttps:\/\/doi.org\/10.1007\/s10552-010-9639-x","journal-title":"Cancer Causes Control"},{"key":"3300_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11060-011-0676-4","volume":"106","author":"LB Chambless","year":"2012","unstructured":"Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC (2012) Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma. J Neurooncol 106:383\u2013389. \nhttps:\/\/doi.org\/10.1007\/s11060-011-0676-4","journal-title":"J Neurooncol"},{"key":"3300_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-013-1150-2","volume":"114","author":"EM Siegel","year":"2013","unstructured":"Siegel EM, Nabors LB, Thompson RC, Olson JJ, Browning JE, Madden MH, Han G, Egan KM (2013) Prediagnostic body weight and survival in high grade glioma. J Neurooncol 114:79\u201384. \nhttps:\/\/doi.org\/10.1007\/s11060-013-1150-2","journal-title":"J Neurooncol"},{"key":"3300_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12707","author":"EK Masel","year":"2017","unstructured":"Masel EK, Berghoff AS, Fureder LM, Heicappell P, Schlieter F, Widhalm G, Gatterbauer B, Dieckmann U, Birner P, Bartsch R, Schur S, Watzke HH, Zielinski CC, Preusser M (2017) Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: a retrospective analysis of 624 patients. Eur J Cancer Care (Engl). \nhttps:\/\/doi.org\/10.1111\/ecc.12707","journal-title":"Eur J Cancer Care (Engl)"},{"key":"3300_CR15","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.2337\/diacare.14.12.1132","volume":"14","author":"P Bjorntorp","year":"1991","unstructured":"Bjorntorp P (1991) Metabolic implications of body fat distribution. Diabetes Care 14:1132\u20131143","journal-title":"Diabetes Care"},{"key":"3300_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1478-7954-8-29","volume":"8","author":"JP Boyle","year":"2010","unstructured":"Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF (2010) Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 8:29. \nhttps:\/\/doi.org\/10.1186\/1478-7954-8-29","journal-title":"Popul Health Metr"},{"key":"3300_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4330\/wjc.v7.i10.603","volume":"7","author":"I Akin","year":"2015","unstructured":"Akin I, Nienaber CA (2015) \"Obesity paradox\" in coronary artery disease. World J Cardiol 7:603\u2013608. \nhttps:\/\/doi.org\/10.4330\/wjc.v7.i10.603","journal-title":"World J Cardiol"},{"key":"3300_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/ijs.12016","volume":"10","author":"KK Andersen","year":"2015","unstructured":"Andersen KK, Olsen TS (2015) The obesity paradox in stroke: lower mortality and lower risk of readmission for recurrent stroke in obese stroke patients. Int J Stroke 10:99\u2013104. \nhttps:\/\/doi.org\/10.1111\/ijs.12016","journal-title":"Int J Stroke"},{"key":"3300_CR19","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamaneurol.2014.1017","volume":"71","author":"C Dehlendorff","year":"2014","unstructured":"Dehlendorff C, Andersen KK, Olsen TS (2014) Body mass index and death by stroke: no obesity paradox. JAMA Neurol 71:978\u2013984. \nhttps:\/\/doi.org\/10.1001\/jamaneurol.2014.1017","journal-title":"JAMA Neurol"},{"key":"3300_CR20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12032-017-0991-5","volume":"34","author":"RJ Klement","year":"2017","unstructured":"Klement RJ (2017) Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation. Med Oncol 34:132. \nhttps:\/\/doi.org\/10.1007\/s12032-017-0991-5","journal-title":"Med Oncol"},{"key":"3300_CR21","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.3892\/ijo.2014.2382","volume":"44","author":"J Rieger","year":"2014","unstructured":"Rieger J, Bahr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kammerer U, Coy JF, Weller M, Steinbach JP (2014) ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol 44:1843\u20131852. \nhttps:\/\/doi.org\/10.3892\/ijo.2014.2382","journal-title":"Int J Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-019-03300-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T23:25:10Z","timestamp":1601335510000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-019-03300-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["3300"],"URL":"https:\/\/doi.org\/10.1007\/s11060-019-03300-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]},"assertion":[{"value":"6 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"NA has received honoraria for advisory board participation from AstraZeneca and research grants from Brainlab AG.PR has received honoraria for advisory board participation and lectures from Bristol-Myers Squibb, Molecular Partners, MSD, Novartis and Roche. RS has received honoraria for advisory boards from Abbvie, Astra Zeneca, Boehringer Ingelheim, MSD, Pfizer, Roche and Takeda. Honoraria as a speaker were received from Astra Zeneca, Boehringer Ingelheim, MSD and Roche. DMC activity for Roche and Takeda was declared as well as financial support for clinical trials by AstraZeneca, BMS, Boehringer Ingelheim, Genentech, MSD, Roche, and Pfizer. MG has received research grants from AstraZeneca and Varian and and honoraria for lectures or advisory board participation or consulting from AstraZeneca. ELR has received research grants from Mundipharma and Amgen and honoraria for lectures or advisory board participation from Abbvie, Daiichi Sankyo, Mundipharma and Novartis. MW has received research grants from Abbvie, Bayer, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, OGD2, Piqur, Roche and Adastra, and honoraria for lectures or advisory board participation or consulting from Abbvie, BMS, Celgene, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Orbus, Roche and Tocagen. FW has received travel support from Roche. AL no conflict of interest declared. RT no conflict of interest declared. BG no conflict of interest declared. RT no conflict of interest declared. SR no conflict of interest declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}